unknown
Stage
2
Investors
About
CellCentric is a clinical-stage biotechnology company focused on developing inobrodib, a first-in-class oral p300/CBP inhibitor for treating specific cancers such as multiple myeloma, prostate cancer, and other hematological malignancies.
Explore CellCentric's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.